The purpose of this paper is to study evidence-based records on the impact of some effective nutraceuticals on major depression disorder management; and describe the antidepressant properties of nutraceuticals to achieve health policy targets and maintain a sustainable healthcare system.
The literature was searched using MEDLINE (PubMed), Google Scholar, PsycINFO and Quertile databases and retrieving relevant published articles in peer-reviewed journals.
The results provided evidence of a range of nutraceuticals with potential benefits in the management of depression. Studies support the anti-depressant properties of S-adenosyl methionine, folnic acid, 5-hydroxytryptophan and omega-3 fatty acids. The results might represent evidence for an innovative adjunctive neurobiological line for the management and treatment of depression.
Randomized-controlled trials and evaluations continue to provide evidence for the use of nutraceuticals in the treatment of depression.
Nutraceuticals emphasize the personalized medicine, which offers a psychophysical balance to the individual.
Nutraceuticals have specific antidepressant properties that may be beneficial in psychiatric populations and reduce pharmacotherapeutic side effects.
Khalifa, N. and Aljaaly, E. (2017), "Using nutraceuticals in the management of major depressive disorder (MDD): Approach to be considered for sustainable healthcare systems", World Journal of Science, Technology and Sustainable Development, Vol. 14 No. 1, pp. 50-59. https://doi.org/10.1108/WJSTSD-01-2016-0007Download as .RIS
Emerald Publishing Limited
Copyright © 2017, Emerald Publishing Limited